Mia's Feed
Medical News & Research

Significant Improvements in Long-Term Survival for Patients with Chronic Thromboembolic Pulmonary Hypertension

Significant Improvements in Long-Term Survival for Patients with Chronic Thromboembolic Pulmonary Hypertension

Share this article

Recent research highlights significant improvements in long-term survival rates among patients with chronic thromboembolic pulmonary hypertension, driven by advances in surgical and medical treatments over recent decades.

2 min read

Chronic thromboembolic pulmonary hypertension (CTEPH) is a condition characterized by elevated blood pressure in the lungs due to blockages, such as blood clots, in the pulmonary arteries. Despite advances in treatment options over recent decades, understanding of long-term patient outcomes has remained limited.

Recent research from Japan has examined patient data spanning from 1980 to 2023, revealing notable improvements in prognosis over time. Historically, patients diagnosed with CTEPH faced poor outcomes owing to limited therapeutic options. However, advancements in surgical techniques and pharmacological treatments have transformed the landscape.

Treatments like pulmonary endarterectomy, which involves surgically removing clots from the lungs, have become more effective. When surgery isn’t feasible, balloon pulmonary angioplasty provides a minimally invasive alternative to widen narrowed blood vessels. Additionally, combining these surgical methods with medical therapies in a multimodal approach tailored to individual patients has shown to enhance outcomes.

The study, published in the European Respiratory Journal, analyzed 834 patients categorized by three eras: early (1980–1999), middle (2000–2010), and recent (2010–2023). The findings demonstrated a significant improvement in survival rates: 68% of patients survived five years in the early era, rising to 85% in the middle era, and reaching 93% in the current era.

Furthermore, the proportion of untreated patients decreased markedly—from 65% in the early period to just 3% today—while the adoption of multimodal treatments increased from none to 58%. Lead researcher Takatoyo Kiko emphasized that these trends reflect increased treatment access and therapeutic strategies.

Although these findings are based on a single center in Japan, they offer hopeful insights into the future management of CTEPH. Ongoing advancements in therapies are expected to further improve patient survival and quality of life in coming decades.

Source: https://medicalxpress.com/news/2025-07-prognosis-chronic-thromboembolic-pulmonary-hypertension.html

Stay Updated with Mia's Feed

Get the latest health & wellness insights delivered straight to your inbox.

How often would you like updates?

We respect your privacy. Unsubscribe at any time.

Related Articles

Global Study Reveals Widening Scale of Infant Malnutrition, Urging Immediate Action

A new global study uncovers the widespread and alarming extent of malnutrition among infants under six months, calling for immediate health interventions to save millions of vulnerable lives.

Dormant Stem Cells Provide Insights into Loss and Decline of Sense of Smell

New research reveals that dormant stem cells in the nose actively support the regeneration of olfactory neurons. These findings may lead to therapies for smell loss caused by aging, infections, or neurological diseases.

Importance of Continued Mammogram Screenings After 75: New Research Indicates Potential Life-Saving Benefits

Recent research shows that continued mammogram screenings after age 75 can lead to earlier detection of breast cancer and potentially save lives. Personalized decisions are recommended.